Dr. Jun Ishigooka, a prominent professor in psychopharmacology attached to Tokyo’s Women’s Medical University School of Medicine has given a great insight into the current trends in drug development for depression and has feedback has added value to this blog post. Depression can affect anyone and it is becoming increasingly common in today’s fast moving […]

In the fast-changing, dynamic healthcare structure, the voice of the patient is becoming increasingly powerful. It’s clear to the pharma world today, that it’s important to have their health practices aligned to enhance consumer experience while adding value to their patients to remain competitive in the market. In this era of digitalisation, the patients have […]

The Asian clinical trial market is expanding rapidly and has now become the main go-to destination for pharmaceutical companies, who are looking to outsource their clinical trials. A large treatment naïve population, together with friendly market reforms and as a region with a high disease burden, it has made Asia a preferred choice today, than […]

At 3H Medi Solutions, we have conducted exhaustive studies about the scope of hypertension in Japan and its various treatment procedures. According to the Japanese society of Hypertension, around 43 million people in Japan are hypertensive and only 50 percent of them undergo any sort of medical treatment. As a result, Hypertension is one of […]

In India, 3H Medi Solutions incorporates the use of unique and highly efficient methods for patient recruitment. These advanced techniques of patient recruitment are based on well thought out and diligently crafted strategies like Site specific Database Management to identify Volunteer Patients, strategically planned recruitments based on protocol requirements and site selection with the help […]

A silent and key player in the sustenance of patient participation for clinical trial and the resultant patient satisfaction is the alignment of mission and values of the clinical trial with the patient goal. In order to understand this, before deciding to participate in the trial it is extremely advantageous for the patient to arrive […]

AstraZeneca K.K. (“AstraZeneca,” Head Office: Kita-ku Osaka-shi, President: Stefan WoxströmA) and CROèe Inc. (“CROèe,” Head Office: Toshima-ku Tokyo, President: Sho Ando) surveyed patients with advanced or recurrent non-small cell lung cancer on their attitudes toward medication. With an increasing number of options, treatment of advanced and recurrent non-small cell lung cancer is becoming more complicated. […]

As a result of having the largest population, China is a country with the highest number of potential patients. Unfortunately, China’s patient pool remains largely untapped due to several country-specific challenges and obstacles. One of the major issues is the lack of widespread awareness within the general Chinese population regarding the clinical trials. Even the […]

As a Patient recruitment specialised Tokyo based PRO-cum-CRO, CROee got an access to a massive database of over 20 million registered patients from more than 400 sites in Japan other than its own 810,000 registered patient under CROee Database. The database includes details of patient’s medical history, hospitalisation-history, symptoms of the disease, participated clinical trials […]

 In Japan, the Pharmaceutical and Medical Device Agency (PMDA) is responsible from the beginning of preliminary non-clinical phases through the late phases including the pivotal clinical trials.  interestingly, increasing fiscal burden and ageing society and decreasing population posing the challenges as well as emergence of unseen opportunities in Japanese pharmaceutical market. Japanese pharma economy is […]